About This Research Desk

What Peptide Cycles is

Peptide Cycles is an independent editorial reference desk covering the published research on three Growth Hormone Axis peptides — CJC-1295, ipamorelin, and MOTS-c — with ipamorelin as the lead compound. The name refers to research cycles: the specific dosing schedules, trial durations, and follow-up windows that scientists have used to study these molecules, not a recommendation for how anyone should personally cycle any compound.

The organizing idea is protocol literacy. A number in a study means something different depending on the design that produced it — a single-dose pharmacokinetic study in eight volunteers is not the same kind of evidence as a 114-person randomized controlled trial, and neither is the same as an observational biomarker association in a hemodialysis cohort. This desk treats the study design as part of the finding, not a footnote to skip past, because that design is what tells a reader how much weight a given number can actually bear.

The three compounds sit at very different points on that evidence curve. CJC-1295 has several small human pharmacokinetic studies and no efficacy trial. Ipamorelin has the most complete human trial record of the three, including a Phase 2 study whose primary endpoint was not met — a result this desk reports rather than reframes. MOTS-c has almost no human interventional data at all, its evidence built instead from cell and rodent work. All three receive the same editorial treatment regardless of how favorable or unfavorable the data happen to look.

How it is compiled

Three principles govern what appears on this site.

First, every quantitative claim is anchored to a numbered citation. Effect sizes, dose levels, sample sizes, trial durations, and statistical results are each tied to a specific source — peer-reviewed journal articles, registered clinical trials, and mechanistic studies, collected with full citation details on the references page.

Second, study design is reported alongside the result, not separately from it. Whether a finding comes from a randomized controlled trial, a single-dose pharmacokinetic study, an observational cohort, or a rodent model is stated plainly wherever the finding appears, because the strength of a claim cannot be separated from the design that produced it.

Third, negative and null results are reported with the same weight as positive ones. Ipamorelin's Phase 2 trial not meeting its primary endpoint appears on this desk with the same prominence as its pharmacokinetic data — omitting or softening a null result would misrepresent the evidence base this desk exists to describe accurately.

What it is not

Peptide Cycles is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. It does not sell, supply, source, or broker any compound, and it has no affiliate or referral relationship with any research-chemical supplier. It does not employ clinicians, diagnose conditions, or prescribe anything, and it does not recommend a dose, schedule, or route of administration for any person, for any of the three compounds it covers.

None of CJC-1295, ipamorelin, or MOTS-c is approved by the FDA or any regulatory body for human use anywhere. All three are sold and handled strictly as research chemicals. Readers seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence on citation corrections or newly published research can be directed to the contact page; this desk monitors that correspondence but cannot respond to requests for medical advice.